Overview

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Status:
Completed

Trial end date:
2019-09-30

Target enrollment:

Participant gender:

Summary

This study evaluates safety and tolerability of a single ascending dose of a tesevatinib liquid formulation administered to pediatric subjects with ARPKD.

Phase:

Phase 1

Details

Lead Sponsor:

Kadmon Corporation, LLC

Treatments:

XL647